Tajikistan · Horizon published · Source published · Reviewed
Tajikistan opens the first phase of Rases Pharma and sets a second-phase expansion plan
Tajikistan’s presidential information service reports the opening of the first phase of Rases Pharma, a Tajik–Indian joint venture established in 2022. Project implementation began in May 2024 under an investment agreement between the Government and Rases Pharma. Four lines are reported in operation for 100 medicines, with stated annual nameplate capacities across tablets, capsules, liquids and topical products. A second phase above 10,000 square metres and TJS 150 million is presented. Official capacity and investment statements require separate verification of licences, certifications, actual output and procurement.
Verified facts
- The official record identifies Rases Pharma as a Tajik–Indian joint venture founded in 2022 and says project implementation began in May 2024 under an investment agreement between the Government and Rases Pharma.
- The first phase has four lines and is reported to have begun production of 100 medicine names, with a planned future range of up to 250.
- Stated annual nameplate capacity is 1.4 billion tablets, 300 million capsules, 21 million units of external-use liquid medicines and 13 million units of ointments, creams and gels.
- The source says equipment and production technology were obtained from the United States, Italy, Germany and Japan and that digital management and a quality-control laboratory are used.
- More than 300 permanent jobs are expected at full first-phase capacity.
- The announced second phase covers more than 10,000 square metres, investment above TJS 150 million, 150 jobs and annual capacity of 125 million units of liquid medicines packaged in ampoules and large plastic containers.
Horizon interpretation
The opening is a concrete industrial-health signal because it identifies an operating phase, product formats, capacity statements, international equipment and a second phase. Nameplate figures and official opening language are not substitutes for audited production, product registration or quality certification. Supplier or distribution decisions should be organized by product, line and regulatory status rather than the total headline capacity.
Business implication / Next checks
Pharmaceutical, laboratory, packaging, cold-chain and compliance teams should monitor three evidence points: the plant and product licences and GMP or other applicable certificates; actual production, registration and market-release data by dosage form; and controlling documentation, financing and procurement for phase two. A case file should capture owner and signatory, product dossier, regulator, quality system, validation, batch release, pharmacovigilance, import/export authorization, raw-material qualification, serialization, storage, distribution, IP, warranty, service, currency and payment protections.
What to verify before acting
Single-source boundary: this brief relies on the Tajik presidential information service’s official opening record. Reported nameplate capacity, investment and jobs do not establish audited output, utilization, product registration, GMP scope, export approval, supplier qualification, a live phase-two procurement, contract, payment or transaction.
Related intelligence
Horizon 8 Nov 2026 · Source 7 Nov 2026
Kazakhstan and Tajikistan sign a twenty-document cooperation package across power, mining and trade
Horizon archive record · Source 14 October 2026
Tajikistan medical-equipment tender highlights supplier and service-readiness requirements
Horizon 8 Nov 2026 · Source 8 Nov 2026
Buston opens an 8,000-tonne rebar line and a 1,600 kW industrial substation
Relevant market platforms
Go deeper
Decision dossiers for this market question
Use the dossier library when the signal needs to become a structured country-sector workstream, rather than a standalone news item.
2026-10-11 · 7 sources
Tajikistan textiles: a full decision dossier for a defined factory, technology, sourcing or cluster proposition
Under what evidence conditions should a machinery supplier, buyer, textile-service firm, investor or sustainability provider advance a Tajikistan proposition to a controlled company-level pilot?
2026-10-12 · 7 sources
Tajikistan health: a full decision dossier for a defined facility, primary-care, medtech or health-services proposition
Under what evidence conditions should a healthcare, medtech, diagnostics, digital-health, WASH, rehabilitation, training or services company advance a Tajikistan proposition to a controlled next step?
2026-10-12 · 6 sources
Tajikistan skills: a full decision dossier for employer-led, safeguarded workforce and training delivery
Under what evidence conditions should a training provider, employer-services firm, workforce-technology company, donor-delivery organisation or investor advance a Tajikistan skills proposition to a bounded pilot?